Android Apple

Intellia reports positive data from Phase II study of NTLA-2002 for HAE

By Yahoo! Finance   |   1 month ago
Intellia reports positive data from Phase II study of NTLA-2002 for HAE

Intellia Therapeutics announces positive results from Phase I/II trial of NTLA-2002, a CRISPR-based gene therapy for hereditary angioedema. Promising reduction in monthly attack rates and potential for a one-time treatment.

Read More

Did you find this insightful?

close

Premium Content

This content is only available for premium members. Please become a paid member to access.

Download App

Currently, memberships can only be purchased through the app.